vs
Caris Life Sciences, Inc.（CAI）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
Caris Life Sciences, Inc.的季度营收约是GRAIL, Inc.的5.0倍（$216.8M vs $43.6M）。Caris Life Sciences, Inc.净利率更高（11.2% vs -227.5%，领先238.7%）。Caris Life Sciences, Inc.同比增速更快（113.4% vs 14.0%）。Caris Life Sciences, Inc.自由现金流更多（$55.3M vs $-63.9M）
Caris生命科学是一家领先的精准医疗生物技术企业，专注于肿瘤领域的先进分子检测服务，为肿瘤医生提供可落地的基因组与分子层面洞察以制定个性化癌症治疗方案，同时与生物制药企业合作加速抗癌新药研发，业务覆盖北美、欧洲及亚太主要市场。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
CAI vs GRAL — 直观对比
营收规模更大
CAI
是对方的5.0倍
$43.6M
营收增速更快
CAI
高出99.4%
14.0%
净利率更高
CAI
高出238.7%
-227.5%
自由现金流更多
CAI
多$119.2M
$-63.9M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $216.8M | $43.6M |
| 净利润 | $24.3M | $-99.2M |
| 毛利率 | — | — |
| 营业利润率 | 15.1% | -285.4% |
| 净利率 | 11.2% | -227.5% |
| 营收同比 | 113.4% | 14.0% |
| 净利润同比 | 135.9% | -2.2% |
| 每股收益（稀释后） | $0.08 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAIGRAL
| Q4 25 | — | $43.6M | ||
| Q3 25 | $216.8M | $36.2M | ||
| Q2 25 | $181.4M | $35.5M | ||
| Q1 25 | — | $31.8M | ||
| Q4 24 | — | $38.3M | ||
| Q3 24 | $101.6M | $28.7M | ||
| Q2 24 | $100.0M | $32.0M | ||
| Q1 24 | — | $26.7M |
净利润CAIGRAL
| Q4 25 | — | $-99.2M | ||
| Q3 25 | $24.3M | $-89.0M | ||
| Q2 25 | $-71.8M | $-114.0M | ||
| Q1 25 | — | $-106.2M | ||
| Q4 24 | — | $-97.1M | ||
| Q3 24 | $-67.7M | $-125.7M | ||
| Q2 24 | $-66.2M | $-1.6B | ||
| Q1 24 | — | $-218.9M |
营业利润率CAIGRAL
| Q4 25 | — | -285.4% | ||
| Q3 25 | 15.1% | -346.2% | ||
| Q2 25 | -9.9% | -446.9% | ||
| Q1 25 | — | -482.5% | ||
| Q4 24 | — | -358.0% | ||
| Q3 24 | -59.9% | -640.5% | ||
| Q2 24 | -67.0% | -5133.8% | ||
| Q1 24 | — | -851.1% |
净利率CAIGRAL
| Q4 25 | — | -227.5% | ||
| Q3 25 | 11.2% | -245.8% | ||
| Q2 25 | -39.6% | -320.7% | ||
| Q1 25 | — | -333.6% | ||
| Q4 24 | — | -253.8% | ||
| Q3 24 | -66.6% | -438.7% | ||
| Q2 24 | -66.2% | -4958.8% | ||
| Q1 24 | — | -819.3% |
每股收益（稀释后）CAIGRAL
| Q4 25 | — | $-2.37 | ||
| Q3 25 | $0.08 | $-2.46 | ||
| Q2 25 | $-7.97 | $-3.18 | ||
| Q1 25 | — | $-3.10 | ||
| Q4 24 | — | $-1.49 | ||
| Q3 24 | $-2.59 | $-3.94 | ||
| Q2 24 | $-2.54 | $-51.06 | ||
| Q1 24 | — | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $755.5M | $249.7M |
| 总债务越低越好 | $375.9M | — |
| 股东权益账面价值 | $478.4M | $2.6B |
| 总资产 | $984.6M | $2.9B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CAIGRAL
| Q4 25 | — | $249.7M | ||
| Q3 25 | $755.5M | $126.9M | ||
| Q2 25 | $721.2M | $127.4M | ||
| Q1 25 | — | $133.9M | ||
| Q4 24 | — | $214.2M | ||
| Q3 24 | — | $853.6M | ||
| Q2 24 | — | $958.8M | ||
| Q1 24 | — | $199.7M |
总债务CAIGRAL
| Q4 25 | — | — | ||
| Q3 25 | $375.9M | — | ||
| Q2 25 | $373.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CAIGRAL
| Q4 25 | — | $2.6B | ||
| Q3 25 | $478.4M | $2.2B | ||
| Q2 25 | $452.9M | $2.3B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | $-2.4B | $2.6B | ||
| Q2 24 | $-2.4B | $2.7B | ||
| Q1 24 | — | — |
总资产CAIGRAL
| Q4 25 | — | $2.9B | ||
| Q3 25 | $984.6M | $2.6B | ||
| Q2 25 | $955.1M | $2.7B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | — |
负债/权益比CAIGRAL
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.4M | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $55.3M | $-63.9M |
| 自由现金流率自由现金流/营收 | 25.5% | -146.5% |
| 资本支出强度资本支出/营收 | 3.3% | 0.2% |
| 现金转化率经营现金流/净利润 | 2.57× | — |
| 过去12个月自由现金流最近4个季度 | — | $-299.9M |
8季度趋势，按日历期对齐
经营现金流CAIGRAL
| Q4 25 | — | $-63.8M | ||
| Q3 25 | $62.4M | $-63.2M | ||
| Q2 25 | — | $-77.0M | ||
| Q1 25 | — | $-95.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-104.6M | ||
| Q2 24 | — | $-171.8M | ||
| Q1 24 | — | $-207.3M |
自由现金流CAIGRAL
| Q4 25 | — | $-63.9M | ||
| Q3 25 | $55.3M | $-63.6M | ||
| Q2 25 | — | $-77.3M | ||
| Q1 25 | — | $-95.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-105.6M | ||
| Q2 24 | — | $-173.2M | ||
| Q1 24 | — | $-209.8M |
自由现金流率CAIGRAL
| Q4 25 | — | -146.5% | ||
| Q3 25 | 25.5% | -175.8% | ||
| Q2 25 | — | -217.6% | ||
| Q1 25 | — | -298.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -368.4% | ||
| Q2 24 | — | -541.7% | ||
| Q1 24 | — | -785.3% |
资本支出强度CAIGRAL
| Q4 25 | — | 0.2% | ||
| Q3 25 | 3.3% | 1.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 9.5% |
现金转化率CAIGRAL
| Q4 25 | — | — | ||
| Q3 25 | 2.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAI
| Molecular Profiling Services | $207.6M | 96% |
| Pharma Research And Development Services | $9.2M | 4% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
